1-4 of 4
Ubaldo Occhini
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anemia Due to Very Low, Low and Intermediate Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts, Who Had an Unsatisfactory Response to or Are Ineligible for Erythropoietin-Based Therapy: A Retrospective Multicenter Study By Fondazione Italiana Sindromi Mielodisplastiche (FiSiM ETS)

Luca Lanino, Prassede Salutari, Alessandra Perego, Bruno Fattizzo, Marta Riva, Marta Ubezio, Pellegrino Musto, Daniela Cilloni, Esther Natalie Oliva, Maria Teresa Voso, Anna Maria Pelizzari, Antonella Poloni, Isabella Capodanno, Chiara Elena, Claudio Fozza, Fabrizio Pane, Massimo Breccia, Marco De Gobbi, Francesco Di Bassiano, Daniela Barraco, Elena Crisà, Dario Ferrero, Chiara Frairia, Antonella Vaccarino, Davide Griguolo, Stefania Paolini, Martina Quintini, Mariarosaria Sessa, Mauro Turrini, Monica Bocchia, Nicola Di Renzo, Elisa Diral, Cristina Foli, Alfredo Molteni, Ubaldo Occhini, Giulia Rivoli, Carmine Selleri, Roberto Bono, Anna Calvisi, Andrea Castelli, Eros Di Bona, Ambra Di Veroli, Luana Fianchi, Sara Galimberti, Daniele Grimaldi, Monia Marchetti, Marianna Norata, Alessandro Rambaldi, Ilaria Tanasi, Patrizia Tosi, Ilaria Naldi, Valeria Santini, Matteo G. Della Porta
Journal: Blood
Blood (2022) 140 (Supplement 1): 6945–6948.
https://doi.org/10.1182/blood-2022-164559
Published: 2022
Journal Articles

Minimal Residual Disease (MRD) at 10 -6 Measured By Next Generation Flow (NGF) during Daratumumab Consolidation Therapy: Analysis at 18 Months Follow up of DART4MM Study (Daratumumab Treatment For Multiple Myeloma Eradication )

Alessandro Gozzetti, Donatella Raspadori, Paola Pacelli, Elisabetta Antonioli, MD, Elena Bestoso, Sara Ciofini, Francesca Bacchiarri, MD, Gabriele Buda, MD PhD, Dania Tocci, Cristiana Cafarelli, Anna Marina Liberati, Piero Galieni, Giulia Lucco Navei, Ubaldo Occhini, Anna Sicuranza, PhD, Michela Staderini, Rosaria Crupi, Mario Petrini, MD PhD, Alberto Bosi, MD, Monica Bocchia
Journal: Blood
Blood (2020) 136 (Supplement 1): 7–8.
https://doi.org/10.1182/blood-2020-141538
Published: 2020
Journal Articles

Safety and efficacy of everolimus, a mTOR inhibitor, as single agent in a phase 1/2 study in patients with myelofibrosis

Clinical Trials & Observations
Paola Guglielmelli, Giovanni Barosi, Alessandro Rambaldi, Roberto Marchioli, Arianna Masciulli, Lorenzo Tozzi, Flavia Biamonte, Niccolò Bartalucci, Elisabetta Gattoni, Maria Letizia Lupo, Guido Finazzi, Alessandro Pancrazzi, Elisabetta Antonioli, Maria Chiara Susini, Lisa Pieri, Elisa Malevolti, Emilio Usala, Ubaldo Occhini, Alberto Grossi, Silvia Caglio, Simona Paratore, Alberto Bosi, Tiziano Barbui, Alessandro M. Vannucchi, on behalf of the AIRC-Gruppo Italiano Malattie Mieloproliferative (AGIMM) investigators
Journal: Blood
Blood (2011) 118 (8): 2069–2076.
https://doi.org/10.1182/blood-2011-01-330563
Published: 2011
Includes: Supplemental data
Journal Articles

Rituximab (R) in Combination with Fludarabine (F) and Cyclophosphamide (C) in Relapsed Follicular Lymphoma (FL) Patients (pts).Final Results of FC + R Phase II Trial by the GISL.

Stefano Sacchi, MD, Samantha Pozzi, MD, Raffaella Marcheselli, BS, Stefano Luminari, MD, Massimo Federico, MD, Alessandra Tucci, MD, Francesco Merli, MD, Loretta Orsucci, MD, Giulia Cervetti, MD, Ubaldo Occhini, MD, Marina Liberati, MD, Vincenzo Callea, MD, Maura Brugiatelli, MD, Luca Baldini, MD
Journal: Blood
Blood (2006) 108 (11): 2763.
https://doi.org/10.1182/blood.V108.11.2763.2763
Published: 2006